AChR-Ab Seropositive Generalized Myasthenia Gravis
Neurology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
argenxEfgartigimod IV
Clinical Trials (1)
Total enrollment: 70 patients across 1 trials
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Start: Dec 2025Est. completion: Mar 202870 patients
Phase 2Recruiting
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
10h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
10h ago
Director of Finance
CoMind
London, UK
10h ago
Electronics Engineering Manager
CoMind
London, UK
10h ago
Director of Information Technology
Zavation Medical Products
10h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 70 patients
1 companies competing in this space